Praxis Precision Medicines Inc (PRAX) - Net Assets
Based on the latest financial reports, Praxis Precision Medicines Inc (PRAX) has net assets worth $878.14 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($937.91 Million) and total liabilities ($59.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Praxis Precision Medicines Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $878.14 Million |
| % of Total Assets | 93.63% |
| Annual Growth Rate | 79.39% |
| 5-Year Change | 250.12% |
| 10-Year Change | N/A |
| Growth Volatility | 256.59 |
Praxis Precision Medicines Inc - Net Assets Trend (2018–2025)
This chart illustrates how Praxis Precision Medicines Inc's net assets have evolved over time, based on quarterly financial data. Also explore Praxis Precision Medicines Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for Praxis Precision Medicines Inc (2018–2025)
The table below shows the annual net assets of Praxis Precision Medicines Inc from 2018 to 2025. For live valuation and market cap data, see PRAX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $878.14 Million | +97.13% |
| 2024-12-31 | $445.45 Million | +539.38% |
| 2023-12-31 | $69.67 Million | -8.46% |
| 2022-12-31 | $76.11 Million | -69.66% |
| 2021-12-31 | $250.81 Million | -12.75% |
| 2020-12-31 | $287.46 Million | +616.62% |
| 2019-12-31 | $40.11 Million | +173.21% |
| 2018-12-31 | $14.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Praxis Precision Medicines Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 109864300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $15.00K | 0.00% |
| Other Components | $2.02 Billion | 229.82% |
| Total Equity | $878.14 Million | 100.00% |
Praxis Precision Medicines Inc Competitors by Market Cap
The table below lists competitors of Praxis Precision Medicines Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ORKLA ADR/1 NK 625
F:OKL0
|
$8.92 Billion |
|
Joby Aviation
NYSE:JOBY
|
$8.92 Billion |
|
Interpublic Group of Companies Inc
NYSE:IPG
|
$8.93 Billion |
|
Guocheng Mining Co Ltd
SHE:000688
|
$8.93 Billion |
|
RHB Bank Bhd
KLSE:1066
|
$8.91 Billion |
|
SouthState Corporation
NASDAQ:SSB
|
$8.91 Billion |
|
HudBay Minerals Inc
TO:HBM
|
$8.90 Billion |
|
Procore Technologies Inc
NYSE:PCOR
|
$8.90 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Praxis Precision Medicines Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 445,450,000 to 878,136,000, a change of 432,686,000 (97.1%).
- Net loss of 303,268,000 reduced equity.
- New share issuances of 690,988,000 increased equity.
- Other comprehensive income decreased equity by 654,000.
- Other factors increased equity by 45,620,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-303.27 Million | -34.54% |
| Share Issuances | $690.99 Million | +78.69% |
| Other Comprehensive Income | $-654.00K | -0.07% |
| Other Changes | $45.62 Million | +5.2% |
| Total Change | $- | 97.13% |
Book Value vs Market Value Analysis
This analysis compares Praxis Precision Medicines Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.31x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 19.54x to 8.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $16.60 | $324.20 | x |
| 2019-12-31 | $35.03 | $324.20 | x |
| 2020-12-31 | $112.67 | $324.20 | x |
| 2021-12-31 | $88.62 | $324.20 | x |
| 2022-12-31 | $24.77 | $324.20 | x |
| 2023-12-31 | $10.57 | $324.20 | x |
| 2024-12-31 | $24.88 | $324.20 | x |
| 2025-12-31 | $39.02 | $324.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Praxis Precision Medicines Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-34.54%) is above the historical average (-111.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -180.73% | 0.00% | 0.00x | 1.35x | $-28.00 Million |
| 2019 | -88.53% | 0.00% | 0.00x | 1.19x | $-39.52 Million |
| 2020 | -21.51% | 0.00% | 0.00x | 1.05x | $-90.57 Million |
| 2021 | -66.54% | 0.00% | 0.00x | 1.17x | $-191.96 Million |
| 2022 | -279.97% | -14554.10% | 0.01x | 1.51x | $-220.68 Million |
| 2023 | -176.95% | -5037.88% | 0.03x | 1.26x | $-130.24 Million |
| 2024 | -41.04% | -2137.48% | 0.02x | 1.08x | $-227.36 Million |
| 2025 | -34.54% | 0.00% | 0.00x | 1.07x | $-391.08 Million |
Industry Comparison
This section compares Praxis Precision Medicines Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Praxis Precision Medicines Inc (PRAX) | $878.14 Million | -180.73% | 0.07x | $8.92 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Soli… Read more